Picture of Veradigm logo

MDRX Veradigm News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid Cap

Allscripts Healthcare Solutions Inc expected to post earnings of 19cents a share - Earnings Preview

* Allscripts Healthcare Solutions Inc  MDRX.OQ   MDRX.O  is
expected to show a fall in quarterly revenue when it reports 
results on November 3. 
    * The Chicago Illinois-based  company is expected to report 
a
58.6% decrease in revenue to $152.805 million from $369.2
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Allscripts
Healthcare
Solutions Inc is for earnings of 19 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allscripts
Healthcare Solutions Inc is $22​, above​ its last closing price
of $14.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  0.15        0.15       0.18      Beat    18.9
 Mar. 31 2022  0.21        0.21       0.13      Missed  -38.6
 Dec. 31 2021  0.35        0.32       0.79      Beat    145.2​
 Sep. 30 2021  0.18        0.18       0.27      Beat    47.3
 ​​Jun.        0.18        0.17       0.23      Beat    31.9
 30 2021                                                
 Mar. 31 2021  0.15        0.15       0.19      Beat    23.5​
 Dec. 31 2020  0.22        0.21       0.29      Beat    36.6
 Sep. 30 2020  0.19        0.19       0.20      Beat    5.6
 This summary was machine generated November 2 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Veradigm

See all news